Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort
暂无分享,去创建一个
M. Davi’ | M. Zatelli | F. Gelsomino | S. Tafuto | M. Cives | S. Pusceddu | A. Raimondi | Alberto Bongiovanni | F. Panzuto | M. Rinzivillo | I. Puliafito | Elisa Andrini | Irene Persano | Giuseppe Lamberti | M.P. Brizzi | Davide Campana
[1] T. Halfdanarson,et al. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. , 2024, Journal of Clinical Oncology.
[2] S. Partelli,et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours , 2023, Journal of neuroendocrinology.
[3] N. Begum,et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET) , 2023, Journal of neuroendocrinology.
[4] M. Falconi,et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes , 2023, Journal of neuroendocrinology.
[5] V. Ambrosini,et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours , 2023, Journal of neuroendocrinology.
[6] M. Falconi,et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3 , 2023, Journal of neuroendocrinology.
[7] C. Ricci,et al. The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis , 2022, Journal of clinical medicine.
[8] E. Baudin,et al. First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with 177Lutetium – Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial, on behalf of the ENDOCAN RENATEN network and G , 2022, Annales d'Endocrinologie.
[9] E. Baudin,et al. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial , 2022, Annals of Oncology.
[10] A. Colao,et al. LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206) , 2022, Annals of Oncology.
[11] S. Severi,et al. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors , 2022, JAMA network open.
[12] E. Mittra,et al. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. , 2021, The Lancet. Oncology.
[13] A. Kjaer,et al. Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors , 2021, Diagnostics.
[14] C. Lombard-Bohas,et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. , 2021, European journal of cancer.
[15] V. Ambrosini,et al. Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials , 2020, Cancers.
[16] M. Galanopoulos,et al. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors , 2020, Neuroendocrinology.
[17] G. Apolone,et al. Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano , 2020, Tumori.
[18] D. Klimstra,et al. Classification of neuroendocrine neoplasms of the digestive system , 2019 .
[19] Lianfeng Zhang,et al. Resection of the primary tumor improves survival in patients with gastro‐entero‐pancreatic neuroendocrine neoplasms with liver metastases: A SEER‐based analysis , 2019, Cancer medicine.
[20] S. Pappas,et al. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors , 2019, Surgery.
[21] J. Ramage,et al. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. , 2018, Seminars in oncology.
[22] Shouhao Zhou,et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.
[23] E. Krenning,et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors , 2017, Clinical Cancer Research.
[24] James C Yao,et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.
[25] E. Krenning,et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site , 2016, Neuroendocrinology.
[26] E. D. de Vries,et al. Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[27] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[28] K. Öberg. Gastrointestinal neuroendocrine tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Manal M. Hassan,et al. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum , 2010, Pancreas.
[30] R. Jensen,et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.
[31] A. Scarpa,et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.
[32] A. Zacharof. Gastrointestinal Neuroendocrine Tumors , 2007 .
[33] Eva Segelov,et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors , 2017, Pancreas.
[34] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.